Effects of Diquafosol Sodium Ophthalmic Solution on Tear Film Matrix Metallopeptidase-9 and Corneal Nerve Density in Patients with Type 2 Diabetic Dry Eye

Qin, Guanghao; Chen, Jiayan; Li, Liangzhe; Qi, Yifan; Chen, Yimeng; Zhang, Qing; Wu, Yi; You, Yue; Yang, Lanting; Guo, Naici; Moutari, Salissou; Bu, Shaochong; Moore, Jonathan E; Xu, Ling; He, Wei; Yu, Sile; He, Xingru; Pazo, Emmanuel Eric

doi:10.1089/jop.2023.0098

Cited by 2 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMP-9 is produced by the corneal epithelium, fibroblasts, and infiltrating leukocytes and is a well-known indicator of inflammation of the tear film 41 – 43 . Several studies have shown a reduction in MMP-9 levels after the use of diquafosol in type 2 diabetic dry eye patients 44 or rebamipide in mouse models 45 . The tear MMP-9 level test is now available as an in-office test and is widely used to diagnose DED.…”

Section: Discussionmentioning

confidence: 99%

Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial

Jin,

Seo,

Kim

2024

Sci Rep

View full text Add to dashboard Cite

This study aimed to compare the clinical efficacy and investigate patients’ preferences for two mucin secretagogues in the treatment of dry eye disease (DED). Thirty patients with DED were randomly treated with either 3% diquafosol or 2% rebamipide ophthalmic solution for 4 weeks, followed by an additional 4-week treatment using the other eye drop after a 2-week washout period. Objective and subjective assessments, including the corneal and conjunctival staining score, tear breakup time (TBUT), Schirmer 1 test, tear osmolarity, tear matrix metalloproteinase-9 (MMP-9), lipid layer thickness (LLT) and ocular surface disease index (OSDI), were performed at baseline, 4 weeks, 6 weeks, and 10 weeks. Patient preferences were assessed based on four categories (comfort, efficacy, convenience, willingness to continue) using a questionnaire and the overall subjective satisfaction score for each drug was obtained at the end of the trial. In total, 28 eyes from 28 patients were included in the analysis. Both diquafosol and rebamipide significantly improved the OSDI (p = 0.033 and 0.034, respectively), TBUT (p < 0.001 and 0.026, respectively), and corneal (p < 0.001 and 0.001, respectively) and conjunctival (p = 0.017 and 0.042, respectively) staining after 4 weeks of treatment. An increase in Schirmer test scores was observed only after rebamipide treatment (p = 0.007). No significant changes were detected in tear osmolarity, MMP-9, and LLT following both treatments. The patients’ preference was slightly greater for diquafosol (46.4%) than rebamipide (36.7%), presumably due to rebamipide's bitter taste. The self-efficacy of both drugs and overall satisfaction scores were comparable. These findings indicate that two mucin secretagogues showed comparable effects in ameliorating symptoms and improving signs (TBUT, corneal and conjunctival staining) in patients with DED.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial

Jin,

Seo,

Kim

2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Many reports have shown the efficacy of DQS ophthalmic solutions in improving corneal staining, stabilizing tear fluid film, and relieving DE symptoms [3–6]. As P2Y 2 receptors are also present in meibomian glands, a DQS-induced increase in the lipid layer has been reported in several studies [7–12]. DQS comprehensively targets the aqueous, mucin, and lipid layers.…”

Section: Introductionmentioning

confidence: 99%

Tolerability of Long-acting Diquafosol Ophthalmic Solution as per Tear Film and Meibomian Glands Findings

Arita,

Fukuoka,

Kaido

2024

Preprint

View full text Add to dashboard Cite

Long-acting diquafosol (DQS) ophthalmic solution (DQS-LX) has significant advantages regarding patient adherence owing to the reduced frequency of required eye drops; however, some patients prefer conventional DQS over DQS-LX. Herein, to clarify the characteristics of patients according to their preference for ophthalmic solutions, dry eye (DE) and meibomian gland (MG) findings were retrospectively investigated. This study enrolled 341 patients with DE (mean age, 62.1 ± 11.7 years) treated at the Itoh Clinic between November 8, 2022, and July 31, 2023, who switched from DQS to DQS-LX. Patients were divided into two groups: those who continued DQS-LX administration (DQS-LX group) and those who wished to revert to conventional DQS (DQS group). Data regarding subjective symptoms assessed using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, tear film breakup time (BUT), tear meniscus height (TMH), corneal and conjunctival fluorescein staining (CFS), conjunctival hyperemia/papilla, meiboscore, plugging, vascularity, meibum grade, and Schirmer’s score at the time of DQS-LX switch were evaluated. Of the 341 patients, 31 (9.1%) wished to revert to conventional DQS. In total, 32 eyes of 16 patients in the DQS group and 64 eyes of 32 patients in the DQS-LX group—for whom complete data were available—were included in the analysis. Compared with the DQS group, the DQS-LX group had significantly higher SPEED scores, shorter BUTs, lower TMHs, greater CFS findings, larger meibum grades (all P < 0.001), lower Schirmer scores (P = 0.008), and more pluggings (P = 0.001) than the DQS group. More allergic conjunctivitis-related complications were observed in the DQS group (P = 0.034). In conclusion, patients with low tear film volume and DE complicated by moderate or severe MG dysfunction preferred DQS-LX, while those with allergic findings preferred conventional DQS.

show abstract

Effects of Diquafosol Sodium Ophthalmic Solution on Tear Film Matrix Metallopeptidase-9 and Corneal Nerve Density in Patients with Type 2 Diabetic Dry Eye

Cited by 2 publications

References 56 publications

Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial

Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial

Tolerability of Long-acting Diquafosol Ophthalmic Solution as per Tear Film and Meibomian Glands Findings

Contact Info

Product

Resources

About